Christensen Thomas Decker, Andersen Niels Trolle, Maegaard Marianne, Hansen Ole Kromann, Hjortdal Vibeke Elisabeth, Hasenkam J Michael
Department of Cardiothoracic and Vascular Surgery and Clinical Institute, Skejby Sygehus, Aarhus University Hospital, Denmark.
Heart Surg Forum. 2004 Jul 1;7(4):E321-5. doi: 10.1532/HSF98.20041000.
Children with congenital heart disease and who are on oral anticoagulation therapy present special challenges due to, for example, rapid fluctuations in international normalized ratio (INR) values, interruption in daily life due to frequent hospital/doctor visits, and difficulties and pain to the child in the performance of venipuncture. We hypothesize that oral anticoagulation therapy can be successfully controlled by self-management for this subset of patients. The aim of this study was to assess the treatment quality of self-managed oral anticoagulation therapy as the proportion of time within the therapeutic INR target range in children with congenital heart disease.
Children (N = 22) with a mean age of 10.6 years (range, 1.8-18.6 years) and their parents were trained in home blood analysis of INR and in coumarin dosage adjustment. After training, the children were monitored by weekly INR measurements. The therapeutic range in target INR values was +/-0.5. The indications for initiating oral anticoagulation therapy were the presence of a mechanical heart valve (n = 16) and total cavopulmonary connection (n = 6). The children had no physical restrictions.
The mean observation time was 3.6 years (range, 0.9-5.8 years), and the total number of patient-years was 75.4. The patients were within the therapeutic INR target range for a median of 73.1% (range, 30.3%-91.0%) of the observation time. Two children died for reasons not related to the oral anticoagulation therapy. None of the patients experienced thromboembolic or bleeding complications requiring doctor intervention.
Self-management of oral anticoagulation therapy is safe and provides a good quality of treatment for selected children with congenital heart disease.
患有先天性心脏病且正在接受口服抗凝治疗的儿童面临特殊挑战,例如国际标准化比值(INR)值快速波动、因频繁就医导致日常生活中断,以及患儿在进行静脉穿刺时面临困难和疼痛。我们假设对于这部分患者,口服抗凝治疗可通过自我管理成功控制。本研究的目的是评估先天性心脏病患儿自我管理口服抗凝治疗的质量,以治疗性INR目标范围内的时间比例来衡量。
对平均年龄为10.6岁(范围1.8 - 18.6岁)的22名儿童及其父母进行家庭INR血液分析和香豆素剂量调整培训。培训后,每周测量INR对儿童进行监测。目标INR值的治疗范围为±0.5。开始口服抗凝治疗的指征为存在机械心脏瓣膜(n = 16)和全腔静脉肺动脉连接(n = 6)。这些儿童无身体限制。
平均观察时间为3.6年(范围0.9 - 5.8年),患者年总数为75.4。患者在治疗性INR目标范围内的时间中位数为观察时间的73.1%(范围30.3% - 91.0%)。两名儿童因与口服抗凝治疗无关的原因死亡。没有患者出现需要医生干预的血栓栓塞或出血并发症。
口服抗凝治疗的自我管理对选定的先天性心脏病患儿是安全的,并提供了良好的治疗质量。